title: The druggability of intracellular nucleotide-degrading enzymes.
abstract: Nucleotide metabolism is the target of a large number of anticancer drugs including antimetabolites and specific enzyme inhibitors. We review scientific findings that over the last 10-15 years have allowed the identification of several intracellular nucleotide-degrading enzymes as cancer drug targets, and discuss further potential therapeutic applications for Rcl, SAMHD1, MTH1 and cN-II. We believe that enzymes involved in nucleotide metabolism represent potent alternatives to conventional cancer chemotherapy targets.
authors.affiliation: Department of Biology, University of Padova, 35131, Padua, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Rampazzo
authors.affiliation: Department of Biology, Biochemistry Unit, University of Pisa, Pisa, Italy.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Tozzi
authors.affiliation: Université de Lyon, 69000, Lyon, France.|Université de Lyon 1, 69622, Lyon, France.|Université de Lyon 1, 69000, Lyon, France.|INSERM U1052, Centre de Recherche en Cancérologie de Lyon, 69000, Lyon, France.|CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, 69000, Lyon, France.|Centre Léon Bérard, 69008, Lyon, France.|Hospices Civils de Lyon, 69000, Lyon, France.
authors.forename: Charles
authors.initials: C
authors.lastname: Dumontet
authors.affiliation: Université de Lyon, 69000, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.|Université de Lyon 1, 69622, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.|Université de Lyon 1, 69000, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.|INSERM U1052, Centre de Recherche en Cancérologie de Lyon, 69000, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.|CNRS UMR 5286, Centre de Recherche en Cancérologie de Lyon, 69000, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.|Centre Léon Bérard, 69008, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.|Equipe Anticorps-Anticancer, INSERM U1052 - CNRS UMR 5286, Faculté Rockefeller, Centre de Recherche en Cancérologie de Lyon, 8 avenue Rockefeller, 69008, Lyon, France. lars-petter.jordheim@univ-lyon1.fr.
authors.forename: Lars Petter
authors.initials: LP
authors.lastname: Jordheim
mesh_terms: D015720:5'-Nucleotidase / Q000037:antagonists & inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D045643:DNA Repair Enzymes / Q000037:antagonists & inhibitors; D055808:Drug Discovery / Q000379:methods*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D058990:Molecular Targeted Therapy; D020559:Monomeric GTP-Binding Proteins / Q000037:antagonists & inhibitors; D009699:N-Glycosyl Hydrolases / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors; D009711:Nucleotides / Q000378:metabolism*; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D000076106:SAM Domain and HD Domain-Containing Protein 1
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009687:Nuclear Proteins; D009711:Nucleotides; D011518:Proto-Oncogene Proteins; D010744:Phosphoric Monoester Hydrolases; D015720:5'-Nucleotidase; C508048:NT5C2 protein, human; D000076106:SAM Domain and HD Domain-Containing Protein 1; C484280:SAMHD1 protein, human; C107935:DNPH1 protein, human; D009699:N-Glycosyl Hydrolases; C078207:8-oxodGTPase; D020559:Monomeric GTP-Binding Proteins; D045643:DNA Repair Enzymes
keywords: MTH1; Nucleotides; Rcl; SAMHD1; cN-II